Alnylam, Sanofi report updated Phase III data for patisiran in FAP

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) reported updated data from the Phase III APOLLO trial of patisiran (ALN-TTR02) in 225 patients with familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis.

On the primary endpoint, 0.3 mg/kg IV patisiran every 3 weeks significantly improved mean modified Neuropathy Impairment Score+7 (mNIS+7) from baseline to 18 months by 34 points compared to placebo (p<0.000000009). Patisiran also significantly improved mean Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) score, a key secondary endpoint, by 21.1 points compared to placebo (p=0.0000000001)...